Australia's most trusted
source of pharma news
Tuesday, 28 July 2026
Posted 28 July 2026 PM
The TGA has given a tick to GSK's new asthma medication, just ahead of a PBAC outcomes announcement.
The IL-5 inhibitor, Exdensur, has been registered to treat severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, currently often treated with GSK's Nucala.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.